2005
Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer Patients
DiGiovanna MP, Stern DF, Edgerton SM, Whalen SG, Moore D, Thor AD. Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer Patients. Journal Of Clinical Oncology 2005, 23: 1152-1160. PMID: 15718311, DOI: 10.1200/jco.2005.09.055.Peer-Reviewed Original ResearchConceptsEpidermal growth factor receptor expressionGrowth factor receptor expressionBreast cancer patientsBreast cancerHuman breast cancerFactor receptor expressionErbB-2Cancer patientsReceptor expressionEGFR expressionEarly-stage breast cancerAdverse prognostic valueErbB-2 phosphorylationFirst clinical evidenceInvasive breast cancerPrognosis of patientsPercent of tumorsParaffin tumor sectionsErbB-2 activationErbB-2 overexpressionLigand-dependent mechanismTreatment of tumorsClinical evidencePrognostic valueShorter survivalPhosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer
Modi S, DiGiovanna MP, Lu Z, Moskowitz C, Panageas KS, Van Poznak C, Hudis CA, Norton L, Tan L, Stern DF, Carter D, Seidman AD. Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer. Cancer Investigation 2005, 23: 483-487. PMID: 16203655, DOI: 10.1080/07357900500201301.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerSingle-agent taxane therapyTaxane therapyP-HER2Clinical benefitBreast cancerClinical resistanceSingle-agent taxane chemotherapyUnique predictive informationChi-squared analysisTaxane chemotherapyClinical outcomesClinical progressionTaxane monotherapyHER2 statusClinical trialsPhosphorylated HER2Tumor specimensFunctional assessmentHER2TherapyMonoclonal antibodiesImmunohistochemistrySquared analysisProgression
2001
Phosphoproteomics
Stern D. Phosphoproteomics. Experimental And Molecular Pathology 2001, 70: 327-331. PMID: 11418011, DOI: 10.1006/exmp.2001.2370.Peer-Reviewed Original Research
2000
Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.
Thor AD, Liu S, Edgerton S, Moore D, Kasowitz KM, Benz CC, Stern DF, DiGiovanna MP. Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer. Journal Of Clinical Oncology 2000, 18: 3230-9. PMID: 10986055, DOI: 10.1200/jco.2000.18.18.3230.Peer-Reviewed Original ResearchConceptsBreast cancerErbB-2 expressionPrognostic valueErbB-2Node-positive breast cancerNode-positive patientsPositive lymph nodesDisease-specific survivalPrimary breast cancerAdditional prognostic valueInvasive breast cancerNode-positive casesBreast cancer patientsSignificant prognostic valueStudy of incidenceArchival breast cancer samplesErbB-2-positive cellsBreast cancer samplesBreast cancer cellsInvasive breast cancer cellsIdentification of casesLymph nodesPatient groupPoor prognosisCancer patients
1996
Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors.
Bacus SS, Chin D, Yarden Y, Zelnick CR, Stern DF. Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors. American Journal Of Pathology 1996, 148: 549-58. PMID: 8579117, PMCID: PMC1861670.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsErbB ReceptorsFemaleFrozen SectionsGenes, erbB-2HumansImmunohistochemistryPhosphorylationPhosphotyrosinePrognosisProto-Oncogene MasReceptor Protein-Tyrosine KinasesReceptor, ErbB-2Receptor, ErbB-4Receptors, EstrogenReceptors, ProgesteroneReceptors, SteroidRetrospective StudiesConceptsMammary carcinomaReceptor tyrosine kinasesType 1 receptor tyrosine kinasesMammary carcinoma patientsType 1 receptorExpression of neuAnti-neu antibodyEpidermal growth factor receptorGrowth factor receptorTyrosine kinaseCarcinoma patientsPrognostic factorsPoor prognosisClinical evaluationTherapeutic strategiesCarcinomaHER-4Frozen sectionsSteroid receptorsNeu/ErbBNeuFactor receptorReceptorsDifferent biological activitiesTyrosine phosphorylation